Don't Miss These Top-Level Speakers
Clinicians*
Tomás Aragón, MD, DrPH, Executive Director - Center for Infectious Disease & Emergency Readiness, University of California, Berkeley
C. Garrison Fathman, MD, Chief Division of Immunology and Rheumatology, Stanford University School of Medicine
Pamela Munster, MD, Associate Professor of Medicine - Division of Hematology/Oncology, University of California, San Francisco
Charles J. Ryan, MD, Associate Clinical Professor of Medicine - Division of Hematology/Oncology, University of California, San Francisco
Industry
Keaven Anderson, Ph.D, Executive Director - Late Development Statistics, Merck Research Laboratories
Alessandra Cesano, MD, Ph.D, Chief Medical Officer, Nodality, Inc.
John Craighead, Ph.D, Managing Director, Investor Relations & Business Development
J. Donald deBethizy, Ph.D, President and CEO, Targacept
Martin Gleave, MD, FRCSC, FACS, Chief Scientific Officer, OncoGenex Pharmaceuticals, Inc.
Mitchell H. Gold, MD, CEO, Dendreon Corporation
Jim Greenwood, President and CEO, Biotechnology Industry Organization
John A. Hardin, MD, Chief Scientific Officer, Arthritis Foundation
Paul J. Hastings, President and Chief Executive Officer, OncoMed
Penny M. Heaton, MD, Vice President and Chief Medical Officer, Novavax
Timothy Herpin, Ph.D, Head of U.S. Search - Strategic Transactions Group, Bristol-Myers Squibb
Roger Hill, Ph.D, MBA, Executive Director - Licensing & Business Development, Boehringer Ingelheim
Andrew A. Hindman, Vice President, Corporate Development, Onyx Pharmaceuticals, Inc
George Kemble, Ph.D, Vice President, Research & Development, Vaccines, MedImmune
J. Joseph Kim, Ph.D, CEO, Inovio Biomedical Corporation
Tod Klingler, Ph.D, Vice President of Information Sciences, XDx Expression Diagnostics
Joseph D. Miller, Ph.D, Chief, Laboratory Preparedness Officer, Influenza Division, Centers for Disease Control and Prevention
Mark Nuttall, Ph.D, Senior Director - Scientific Licensing, Johnson & Johnson
Craig C. Parker, Senior Vice President, Finance & Corporate Development, & Chief Financial Officer, Proteolix, Inc.
Sandra C. Raymond, President and CEO, Lupus Foundation of America
Timothy C. Rodell, MD, President and CEO, GlobeImmune, Inc.
Ellen E. Sheets, MD, Chief Medical Officer, Predictive Biosciences
Alan M. Solinger, MD, FACP, FACR, Vice President of Clinical Immunology, XOMA
Rahul Singhvi, Sc.D., MBA, President and CEO, Novavax
Howard R. Soule, Ph.D, Chief Scientific Officer, Prostate Cancer Foundation
Peter A. Thompson, MD, FACP, President & CEO, Trubion Pharmaceuticals
Investors & Analysts
David Bowen, Ph.D, Staff Director, Health Policy, Senate Health, Education, Labor and Pensions Committee
Jim Birchenough, MD, Director, US Biotechnology Equity Research; Barclay's Capital
Christopher D. Earl, Ph.D, former President and CEO, BIO Ventures for Global Health (BVGH)
Michelle S. Doig, Principal, Corporate Finance, Abingworth
Ashley Dombkowski, Ph.D, Managing Director, MPM Capital
Michelle Easton, Partner, Tarplin, Downs and Young, LLC
Howard Furst, MD, Partner, Deerfield Management
Marc Grasso, MD, Managing Director, Head of West Coast Investment Banking, Leerink Swann
Jeffrey R. Greene, Global Transactions Leader, Life Sciences, Ernst & Young LLP
Ronald W. Lennox, D.Phil, Partner, CHL Medical Partners
Daniel Lyons, Ph.D, CFA, Equity Research Analyst, Janus Funds
Evan McCullough, CFA, Vice President and Portfolio Manager, Franklin Templeton Investments
George Milstein, Managing Director, Healthcare Mergers and Acquisitions, Wedbush PacGrow Life Sciences
Liana Moussatos, Ph.D, Senior Healthcare Research Analyst, WedBush PacGrow Life Sciences
Oleg Nodelman, Porfolio Manager, Biotechnology Value Fund, LP
Deepa Pakianathan, Ph.D, Partner, Delphi Ventures
Heather Preston, MD, Managing Director, TPG Biotech
Bryan Roberts, Ph.D, Partner, Venrock
Joel Verter, Ph.D, Senior Vice President, Statistic Collaborative, Inc.
Rick Weissenstein, Senior Vice President, Healthcare Services Analyst, Washington Research Group
Darren Willcox, Principal, Dutko Worldwide, Former Senior Health Advisor for Speaker Dennis Hastert
*BIO is proud to be working with Panel Intelligence, formerly MedPanel, Inc., to provide leading industry experts on these therapeutic workshops. As a fully committed and capable research partner, Panel Intelligence works closely with BIO to identify objectives, recruit experts, elicit information, and synthesize results. Panel Intelligence's domain expertise, global network of experts, and proven online methods can provide due diligence on one particular company, investigate a particular space, evaluate an IPO, or identify market trends and consumer preferences.